Vitamin D (VtD) endocrine system is associated with obesity. The relationship between VtD and body fat was described originally by Lumb et al. [1] . Subsequently murine experiment and human study revealed that body fat is the major storage site of vitamin D3 and the source for other VtD metabolites during deprivation as well [2, 3] . The reasons of VtD insuffi ciency in obese people have been postulated to several factors such as a decrease exposure to sunlight because of low activity level, a negative feedback from elevated active VtD metabolite 1,25-hydroxyvitamin D and parathyroid hormone (PTH) levels on hepatic synthesis of 25-OHD [4] , and the metabolic clearance of VtD may increase in obesity with enhanced uptake by adipose tissue [5] . Recently, Worstman et al. [6] also demonstrated that obesity-associated VtD insuffi ciency most likely ORIGINAL ARTICLE Korean J Obstet Gynecol 2012;55(6) Objective Obesity is associated with alterations in vitamin D (VtD) system. We evaluated the correlation between VtD level and body mass index (BMI), a standard for the evaluation of obesity in postmenopausal women.
Sun Young Jang, et al. Vitamin D and BMI in postmenopause is due to decreased bioavailability of vitamin D3 from cutaneous and dietary sources because of its deposition in body fat compartments. Although studies to determine the ideal VtD concentration in the blood have been carried out recently, their conclusions remain controversial. The ideal VtD level can be defi ned as the concentration at which calcium absorption is at its maximum and parathyroid hormone levels in the blood are most suppressed such that high bone density is maintained, while the risks of osteopenia and falls or fractures are minimized. Various studies have suggested different ideal levels. The range of 50-80 nmol/L (20-32 ng/mL) has generally been considered the ideal for healthy bone [7] . According to this standard, the prevalence of VtD defi ciency is high throughout the world [8] . Low level of VtD is characterized by mild secondary hyperparathyroidism and enhanced risk of osteoporotic fracture. Several well known factors that were infl uence on serum VtD level were seasons, dietary VtD intake, ethnicity, age, and possibly adipose tissue. However, it still remains unknown whether obesity should be taken into consideration while assessing and managing VtD deficiency. We studied the correlation between VtD level and body mass index (BMI), a standard for the evaluation of obesity in healthy postmenopausal women.
Materials and Methods
We evaluated 310 postmenopausal women who visited the outpatient postmenopausal clinic at 3 universities between January 2005 and March 2011. Exclusion criteria consisted of any chronic illness including hypertension, diabetes, renal, hepatic, or coronary disease; medications known to affect bone metabolism; and any use of hormonal replacement therapy. Age, BMI, menopausal period, bone mineral density (BMD), serum 25-hydroxyvitamin D level, bone turnover markers, and parathyroid hormone level were measured. Blood was collected between 9:00 and 11:00 AM after overnight fasting. BMD was measured by dual energy X-ray absorptiometry of the lumbar spine (GE lunar Prodigy, Madison, WI, USA). Osteocalcin and N-telopeptide were measured as bone turnover markers. 25-hydroxyvitamin D levels in the blood was measured by radioimmunoassay (RIA) with a 25-OH vitamin D 125 RIA kit (Sorin Diagnostics Inc., France). The parathyroid hormone level was measured by immunoradiometric assay (IRMA) with a DSL-8000 Active intact PTH IRMA kit (Diagnostic System Laboratories Inc., USA).
Serum osteocalcin was measured by RIA, using a rabbit polyclonal antiserum raised against bovine osteocalcin. N-telopeptide was measured by enzyme-linked immunosorbent assay (ELISA), using monoclonal antibody for human N-telopeptide. Chapuy et al. [9] referred to serum VtD insufficiency when it is lower than 30 ng/mL while Lips et al. [10] 
Results

Demographic characteristics
Total 310 healthy postmenopausal women were included in this study between January 2005 and March 2011. The baseline demographic profi le of our study were age, height, weight, BMI, Table 1 . Clinical characteristics of the subjects (n = 310)
Variables
Mean ± standard deviation
Age (yr) 57.5 ± 5.9
Height ( menopausal period, total lumbar BMD, 25-hydroxy-vitamin D (25-OH-VtD), PTH, osteocalcin and N-telopeptide and highlighted in Table 1 .
Classifi cation by VtD level in blood
With a standard for VtD defi ciency in blood of 30 ng/mL, 307 patients (99.0%) had levels under 30 ng/mL, and only 3 patients (1%) had levels over 30 ng/mL. However, following Lips' standard of 20 ng/mL, 250 patients (87.7%) had levels under 20 ng/mL and 26 patients (12.3%) had levels over 20 ng/mL [10] . Furthermore, with a standard of 10 ng/mL for VtD defi ciency, only 126 patients (40.6%) had levels under 10 ng/mL with the remainder over the minimum standard (Table 2 ).
Comparing each variable between two groups -those <20 ng/mL and ≥20 ng/mL of VtD concentration -the levels showed a significant difference at 10.9 ng/mL versus 26.3 ng/mL. In addition, PTH levels were also signifi cantly low at 17.4 pg/mL in the group with ≥20 ng/mL of VtD in the blood versus 23.1 pg/mL of in the group <20 ng/mL. However, other variables including BMI did not show significant differences (Table 3) . However, no significant differences were found between the <10 ng/mL and the 10-20 ng/mL groups, or between the 10-20 ng/mL and the ≥20 ng/mL concentration groups. Among the other variables, including BMI, no other signifi cant differences were found.
Correlation analysis between VtD level in blood
and each variable Age, height, weight, BMD, osteocalcin, and N-telopeptide did not show signifi cant differences according to VtD level; however, parathyroid hormone level showed a negative correlation of -0.20 (P=0.0012) ( Table 4) .
Correlation analysis among VtD level, PTH level in
blood, and BMI Analyzing correlation between VtD level in blood and each variable with regression analysis, there was a negative correlation of -0.066 between BMI and VtD level; however, the difference was not statistically signifi cant (P=0.42). In addition, there was a positive correlation of 0.0936 between BMI and PTH level; however, 
Discussion
This is a cross-sectional, hospital-based study that try to provide the evidence, obesity defi ned by BMI is determining factor of serum VtD level. BMI, calculated from height and body weight, is widely adopted to determine obesity which increases the risk of cardiovascular disease, hypertension, and diabetes [11] . BMI is accepted as index of body fat thanks to high correlation between BMI and body fat percentage although BMI per se does not indicate body fat itself.
In this context, we analyzed the relation between BMI versus serum VtD level. VtD plays a central role in calcium and phosphorus homeostasis and skeletal health. Various standards for identifying VtD defi ciency have been reported. Since impaired calcium metabolism due to low serum 25-OH-VtD levels triggers secondary hyperparathyroidism, increased bone turnover, and progressive bone loss [12] , the optimal range of circulating 25-OH-VtD for skeletal health has been proposed as the range that reduces PTH levels to a minimum [13] and calcium absorption is maximal. Several studies have shown that PTH levels plateau to a minimum steady-state level as serum 25-OH-VtD levels approach and rise above approximately 30 ng/mL (75 nmol/L) [14] . Chapuy et al. [10] reported that a large percentage of the French adult urban population has VtD insuffi ciency during wintertime and that an increase in serum PTH secretion is initiated as soon as the serum 25-OH-VtD level falls below 78 nmol/L (31 ng/mL), which is currently considered a normal value for 25-OH-VtD. Our study was performed in the winter, so when we adopted Chapuy and colleagues' standard of 30 ng/ mL for the winter, 307 menopausal women, all but 3 (99.0%) among 310, had a VtD defi ciency. We also tried to compare parathyroid hormone levels among groups to decide the ideal VtD level in our study, there was no signifi cant difference between the group with ≥30 ng/mL and the group with <30 ng/mL of VtD concentration. However, there was a signifi cant difference between the group with ≥20 ng/mL and the group with <20 ng/mL. Comparing parathyroid hormone levels after the groups were stratifi ed by every 2.5 ng/mL of VtD concentration, parathyroid hormone levels were maintained rather than decreased in the 20-22.5 ng/mL group, while hyperparathyroidism was not observed in the groups over 20 ng/mL (data no shown). Hence we grouped according to the VtD level of 20 ng/mL and compared the demographic variables. Obesity determined by BMI was high when VtD was less than 20 ng/mL although it was not statistically signifi cant (Table 2) . Obese individuals, as a group, have low VtD levels, which are associated with increased plasma concentration of immunoreactive parathyroid hormone [14, 15] . It was reported that adipose tissue isolates VtD in a person who has a high BMI, which, in turn, causes serum VtD level to decrease. Tsiaras and Weinstock [16] investigated the relationship between obesity and VtD defi ciency. Their study reported that there was no difference in ability to synthesize VtD between normal and obese people; however, the reason for VtD defi ciency was the decrease in secretion of VtD from the skin to the blood because VtD was isolated in the adipose tissue of the obese. On the contrary, Arunabh et al. [17] reported that blood VtD concentration was related to body fat content, not BMI or weight. They explained that adipose tissue content itself, not BMI, affected VtD level because VtD distribution was changed in the adipose tissue. This discrepancy may be explained by that high BMI people usually show not only high total body fat but also high total muscle mass, and high muscle mass was showed positive correlation with VtD [16] . Reasons for VtD defi ciency can include skin color, adipose tissue content in the body, taking drugs, fat absorption disorder, and increasing age, as well as physical factors such as clothes and sunscreen. BMI was not correlated to serum VtD level or PTH in this study. Scott et al. [18] reported VtD level is more affected by individual activity level rather than individual BMI [16] . Thus physical activity of elderly in particular should be taken into account. The subjects in this study are biased toward certain geographical locations, and the number of subjects used to generate data on VtD level in Korean menopausal women was relatively small, in that only 3 cases showed a level over 30 ng/mL level. Therefore, comparing the two groups using a standard of 30 ng/mL had its limitations. This limitation could be overcome in future studies by collecting subjects from a wider variety of geographic locations.
In conclusion, most Korean menopausal women show VtD deficiency, especially during the wintertime and VtD level show negative correlation with BMI, but statistically not signifi cant.
